Albert A Davis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8159168/publications.pdf

Version: 2024-02-01

759233 794594 26 882 12 19 h-index citations g-index papers 29 29 29 1767 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid- \hat{l}^2 and other amyloidogenic proteins. Journal of Lipid Research, 2017, 58, 824-836.	4.2	159
2	Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression. Neurobiology of Aging, 2016, 37, 209.e1-209.e7.	3.1	106
3	<i>APOE</i> genotype regulates pathology and disease progression in synucleinopathy. Science Translational Medicine, 2020, 12, .	12.4	102
4	Intercellular Spread of Protein Aggregates in Neurodegenerative Disease. Annual Review of Cell and Developmental Biology, 2018, 34, 545-568.	9.4	99
5	Solving neurodegeneration: common mechanisms and strategies for new treatments. Molecular Neurodegeneration, 2022, 17, 23.	10.8	83
6	Resequencing analysis of five Mendelian genes andÂthe top genes from genome-wide association studies in Parkinson's Disease. Molecular Neurodegeneration, 2016, 11, 29.	10.8	70
7	Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. BMC Neurology, 2017, 17, 198.	1.8	55
8	TDP-43 dysfunction results in R-loop accumulation and DNA replication defects. Journal of Cell Science, 2020, 133, .	2.0	35
9	Parkinson disease and cognitive impairment. Neurology: Clinical Practice, 2016, 6, 452-458.	1.6	34
10	Is Levodopa Response a Valid Indicator of Parkinson's Disease?. Movement Disorders, 2021, 36, 948-954.	3.9	26
11	Overlapping genetic architecture between Parkinson disease and melanoma. Acta Neuropathologica, 2020, 139, 347-364.	7.7	23
12	Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. Frontiers in Neuroscience, 2018, 12, 230.	2.8	21
13	VCP suppresses proteopathic seeding in neurons. Molecular Neurodegeneration, 2022, 17, 30.	10.8	15
14	<i>MAPT</i> R406W increases tau T217 phosphorylation in absence of amyloid pathology. Annals of Clinical and Translational Neurology, 2021, 8, 1817-1830.	3.7	11
15	TMEM230 in Parkinson's disease. Neurobiology of Aging, 2017, 56, 212.e1-212.e3.	3.1	9
16	A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 63-71.	2.8	9
17	Cerebrovascular Events After Continuous-Flow Left Ventricular Assist Devices. Neurocritical Care, 2018, 29, 225-232.	2.4	8
18	Functional genomic analyses uncover APOE-mediated regulationÂofÂbrain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. Acta Neuropathologica Communications, 2020, 8, 196.	5.2	8

ALBERT A DAVIS

#	Article	IF	CITATIONS
19	Leaky pipes: Tau and apoE implicated in blood-brain barrier dysfunction in Alzheimer disease. Science Translational Medicine, 2020, 12, .	12.4	6
20	Beyond synuclein: Organelle accumulation in Lewy bodies may drive neurodegeneration. Science Translational Medicine, 2020, 12, .	12.4	1
21	Tau kinetics in Alzheimer disease and primary tauopathies. Alzheimer's and Dementia, 2020, 16, e039109.	0.8	0
22	A QuICR test to diagnose Parkinson's disease. Science Translational Medicine, 2021, 13, .	12.4	0
23	In on the ground floor: T cells respond to α-synuclein in preclinical Parkinson's disease. Science Translational Medicine, 2020, 12, .	12.4	0
24	Plasma proteins have a ticket to ride the blood-brain barrier. Science Translational Medicine, 2020, 12, .	12.4	0
25	Partners in crime: \hat{l}_{\pm} -synuclein modulates pathologic tau spreading. Science Translational Medicine, 2020, 12, .	12.4	0
26	Astrocytic BMAL1 regulates protein aggregation in mouse models of alphaâ€synuclein and tau pathology. Alzheimer's and Dementia, 2021, 17, e058631.	0.8	0